Valid for Submission
Q85.09 is a billable code used to specify a medical diagnosis of other neurofibromatosis. The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code Q85.09 might also be used to specify conditions or terms like segmental neurofibromatosis. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.
|Short Description:||Other neurofibromatosis|
|Long Description:||Other neurofibromatosis|
Index to Diseases and Injuries
The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for the code Q85.09 are found in the index:
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Segmental neurofibromatosis
- NEUROFIBROMATOSIS 1-. an autosomal dominant inherited disorder with a high frequency of spontaneous mutations that features developmental changes in the nervous system muscles bones and skin most notably in tissue derived from the embryonic neural crest. multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. peripheral and central nervous system neoplasms occur frequently especially optic nerve glioma and neurofibrosarcoma. nf1 is caused by mutations which inactivate the nf1 gene genes neurofibromatosis 1 on chromosome 17q. the incidence of learning disabilities is also elevated in this condition. from adams et al. principles of neurology 6th ed pp1014 18 there is overlap of clinical features with noonan syndrome in a syndrome called neurofibromatosis noonan syndrome. both the ptpn11 and nf1 gene products are involved in the signal transduction pathway of ras ras proteins.
- GENES NEUROFIBROMATOSIS 1-. tumor suppressor genes located on the long arm of human chromosome 17 in the region 17q11.2. mutation of these genes is thought to cause neurofibromatosis 1 watson syndrome and leopard syndrome.
- GENES NEUROFIBROMATOSIS 2-. tumor suppressor genes located on the long arm of human chromosome 22. mutation or loss of these genes causes neurofibromatosis 2.
- NEUROFIBROMATOSIS 2-. an autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas neurilemmoma of other cranial and peripheral nerves and other benign intracranial tumors including meningiomas ependymomas spinal neurofibromas and gliomas. the disease has been linked to mutations of the nf2 gene genes neurofibromatosis 2 on chromosome 22 22q12 and usually presents clinically in the first or second decade of life.
- NEUROFIBROMATOSES-. a group of disorders characterized by an autosomal dominant pattern of inheritance with high rates of spontaneous mutation and multiple neurofibromas or neurilemmomas. neurofibromatosis 1 generalized neurofibromatosis accounts for approximately 95% of cases although multiple additional subtypes e.g. neurofibromatosis 2 neurofibromatosis 3 etc. have been described. from neurochirurgie 1998 nov;444:267 72
- NEUROFIBROMIN 1-. a protein found most abundantly in the nervous system. defects or deficiencies in this protein are associated with neurofibromatosis 1 watson syndrome and leopard syndrome. mutations in the gene gene neurofibromatosis 1 affect two known functions: regulation of ras gtpase and tumor suppression.
- NEUROFIBROMIN 2-. a membrane protein homologous to the erm ezrin radixin moesin family of cytoskeleton associated proteins which regulate physical properties of membranes. alterations in neurofibromin 2 are the cause of neurofibromatosis 2.
Present on Admission (POA)
Q85.09 is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here .
CMS POA Indicator Options and Definitions
|POA Indicator Code||POA Reason for Code||CMS will pay the CC/MCC DRG?|
|Y||Diagnosis was present at time of inpatient admission.||YES|
|N||Diagnosis was not present at time of inpatient admission.||NO|
|U||Documentation insufficient to determine if the condition was present at the time of inpatient admission.||NO|
|W||Clinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.||YES|
|1||Unreported/Not used - Exempt from POA reporting. ||NO|
Convert Q85.09 to ICD-9
- 237.79 - Neurofibromatosis NEC
Congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)
Other congenital malformations (Q80-Q89)
Phakomatoses, not elsewhere classified (Q85)
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
(First year ICD-10-CM implemented into the HIPAA code set)
- FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020